

The impact of gender in cardiovascular medicine: Lessons from the gender/sex-issue in heart failure

Alberto M. Marra¹, Andrea Salzano^{2,3}, Michele Arcopinto², Lucrezia Piccioli², Valeria Raparelli^{4,5}

¹ *IRCSS SDN, Naples, Italy*

² *Department of Translational Medical Sciences, Federico II University, Naples, Italy*

³ *Department of Cardiovascular Sciences & NIHR Leicester Cardiovascular Biomedical Research Centre, University of Leicester, Glenfield Hospital, Leicester, UK*

⁴ *Department of Experimental Medicine, Sapienza University of Rome, Italy*

⁵ *Center for Outcomes Research and Evaluation, Research Institute, McGill University Health Centre, Montreal, Canada*

Abstract

Heart Failure (HF) is a major healthcare issue, given its high prevalence and incidence, the rate of comorbidities, the related high healthcare costs and its poor outcome. In the last years mounting evidence revealed several differences between men and women affected by this clinical condition. Apart from the well-known difference in phenotype (HF with reduced ejection fraction (HFrEF) occurs more commonly in men, and HF with preserved ejection fraction (HFpEF) is more frequent in women) other relevant sex-related issues dwell upon epidemiology, presentation, risk stratification and management. These differences shed new lights on the possibility to consider HF as a prototype of the impact of gender/sex issue in cardiovascular medicine. A call for action and future strategies might help in the achievement of a cleaver patient-care.

Corresponding author: Dr. Alberto M. Marra, IRCSS SDN, Via Gianturco 131, 80143 Naples, Italy. Tel./Fax: +39.081.8907452.
E-mail: alberto_marra@hotmail.it

Key words: Heart Failure; sex; gender.

Contributions: AMM, AS, study concept, manuscript first draft writing; LP, MA, systematic review of the literature; VS, suggestions and inputs to study design.

Received for publication: 13 August 2018

Accepted for publication: 17 September 2018

©Copyright A.M. Marra et al., 2018

Tipografia PI-ME Editrice, Italy

Monaldi Archives for Chest Disease 2018; 88:988

doi: [10.4081/monaldi.2018.988](https://doi.org/10.4081/monaldi.2018.988)

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Introduction

Heart Failure (HF) is a major healthcare problem with a global prevalence of more than 25 million, and this figure is estimated to grow in the forthcoming years [1,2], HF might represent the terminal stage of theoretically all cardiovascular diseases and is still burdened by a poor prognosis with a 5 years mortality of 50% and often patients are affected by concomitant comorbidity, which dramatically increase the related health-care costs [3,4]. Although HF affects equally men and women, the latter are remarkably underrepresented in clinical trials[5,6]. Moreover, is noteworthy the bimodal pattern of HF incidence, being higher in men at younger ages and higher in women after 80-years old [7]. On top of these observations, men and women present with different phenotypes of HF, being the latter more often affected by HF with preserved ejection fraction (HFpEF) than HF with reduced ejection fraction (HFrEF) [8]. Given this magnitude, the existing differences between the two sexes make the management of HF patients more challenging. In this review, we will focus on the main sex-related differences of heart failure pathophysiology, clinical features, and therapy and how this could impact the clinical practice of this condition.

Pathophysiological underpinnings of the different presentation of HF in men and women

HF is characterized by the overexpression of molecular and hormonal pattern (such as angiotensin-aldosterone pathways, adrenergic activation and inflammation) after an index event aimed at restoring the homeostasis of the cardiovascular system [9,10]. However, this process might ultimately result into a maladaptive remodeling of the left ventricle with long-term detrimental effects on the cardiovascular system [11-17].

As mentioned above, the age of HF-diagnosis is higher in women [7]. Moreover, risk factors act differently in female subjects compared with males. For instance, diabetes mellitus confers a 3-fold higher risk to develop HF in women, compared with a 2-fold risk in men [18]. Obesity is a more common comorbidity in women with HF than in men [19]. Moreover, systemic hypertension is more prevalent in women than in men at HF diagnosis [19]. On the other hand, the most

common cause of HF in men is ischemic cardiomyopathy [20]. Furthermore, hormones acts differently on the cardiovascular system of men and women [21-32]. All these factors ultimately lead to different structural phenotype of the left ventricle (LV). While female tends to present with reduced volumes, higher contractility and concentric remodeling, typically males HF patients are characterized by eccentric remodeling with higher volumes and reduced ejection fraction [33,34]. Usually women presents also with smaller right ventricles with concomitant RV systolic function similar to men which ultimately leads to reduced wall-stress [35-41]. However, although this paradigm (HF_rEF in young/males, HF_pEF in females) might be helpful to summaries, it does not prejudge the fact that young women/females may have HF_rEF and old me/males may have HF_pEF. Interestingly, some HF etiologies belong exclusively to female sex, such as peripartum cardiomyopathy, likewise other involves primarily women including connective tissue diseases, autoimmunity and chemotherapy [33]. Also, the so-called Takotsubo cardiomyopathy, a form of stress-induced cardiomyopathy, which leads to reversible acute HF, is predominant in post-menopausal women [42]. This body of evidence points to a higher prevalence of HF_rEF phenotype in males, whereas females are more often affected by HF_pEF. Symptoms also differ between the two sexes, with women more prone to develop shortness of breath associated with reduced exercise capacity and pulmonary edema [43]. Of note, also natriuretic peptides concentrations are higher in HF-females patients than in men [44,45].

Different effects of HF-treatment between the two-sexes and their impact on prognosis

While clinical trials brought about positive results in terms of reduction of hard clinical outcomes in HF_rEF, we still did not develop a specific and targeted therapy for patients with HF_pEF [46]. With regards to the use of angiotensin converting enzyme inhibitors (ACE-inh) and angiotensin receptor blockers (Arbs), they share similar effects in both sexes[47,48], with small differences in favor of a more noticeable positive effects in males according to post-hoc analysis of clinical trials [47]. Of note, women are more prone to develop angioedema and other side effects of ACE-inhibitors [49]. Beta-blockers showed similar positive results in men as well as in women, with a slightly more survival benefit in old-women [50]. However, when considering the effectiveness of implantable cardioverter-defibrillators (ICD) in women with heart failure (HF), several concerns arose in the last years. Pooled data of 5 trials showed no benefit in the prevention of sudden cardiac death in 934 women (HR: 1.01, 5-95% CI: 0.76-1.33) [51]. Another meta-analysis also demonstrated that women have a 70% increase in adverse events with ICD implantation compared to men [52]. Given these findings, it is surprising that no prospective trial has been ever implemented in women, also taking into account that 30% of ICD implantation are performed in the female population [53]. Surprisingly, women seem to benefit more than men from the use of cardiac resynchronization therapy (CRT). According to a post-hoc analysis of the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT) trial, women experienced a greater survival benefit and reduction of hospitalization, accompanied by a remarkable reverse remodeling of left ventricle when compared to the male counterpart [54,55]. In these regards, it is worth to mention that there are apparently no differences regarding prognosis in two sexes, although women without ischemic heart disease generally lives longer than men [56]. On the other hand, women are more prone to develop HF after myocardial infarction than men [5,6].

Heart Failure as a prototype for considering the importance of the sex/gender issue in cardiovascular medicine

The aforementioned evidence stresses the concept that an improved awareness of the gender/sex-issues in HF might represent a “fly-wheel” of a needed paradigm-switch, not only in HF-care, but in the full spectrum of cardiovascular medicine. This finding underlines again the concept that sex and gender differences should be considered as an important unmet need of clinical research. Because of the lack of evidence, in part due to the circumstance that animal-models and large clinical trials classically have involved almost always males, in last few years a growing interest in this topic was recorded [57,58].

Indeed, even if greater efforts are eagerly needed to promote this topic in basic and clinical research, there is still a very poor knowledge about the proper role of the biological differences among male and female [58]. While it may be anticipated that the recent regulations of the National Institutes of Health may in all likelihood modify this trend in the future years, there is no doubt that such poor awareness of female differences in physiology, clinical features [59] and response to therapeutic interventions and drugs [60,61] led worldwide women to experience an inequitable health care assistance compared to men [62-64]. In this regard, it must be stressed that current guidelines are based on clinical trials that involved predominantly men.

In the age of personalized medicine, it is surprising that in clinical decision-making is still paid poor attention to the patient’s sex, a concept that should represent a gold standard of clinical practice [65].

Another fundamental issue relates to the correct terminology, being sex and gender frequently used wrongly and considered as indicating the same term. On the one hand, the expression sex is related to biological characteristics including chromosomes, hormones, gene expression, and reproductive anatomy. On the other hand, gender is perhaps a more complex concept that includes the socially-constructed roles, behaviors, expressions, and identities of girls, women, boys, men and gender-diverse people [65]. Thus, gender identity may change over time, being not confined to a binary dichotomy. Compared to sex, gender could not be considered as static and it exists along a continuum. In this regard, a landmark study was recently published [66]. Pelletier *et al.* for the first time assessed the relevance of a composite measure of gender [67] as a tool to stratify the risk of death in a cohort of acute coronary syndrome (ACS) patients. According to this interesting study, the presence of a feminine role accompanied by personality traits was more significantly associated with recurrent acute coronary syndrome than subjects with a masculine profile, and represented an independent predictor of ACS (hazard ratio from score 0 to 100: 4.50; 95% confidence interval: 1.05 to 19.27). These findings led to the speculation that feminine characteristics are more useful to assess the risk of hard outcomes in cardiovascular diseases than the sex (biological variable) itself.

According to several international societies, 4 interconnected aspects cover the gender concept: gender identity (*e.g.*, personality traits), gender roles (*e.g.*, child care), gender relationships (*e.g.*, social support), and what is termed “institutionalized gender” (*e.g.*, education level, personal income). Thus, gender-related factors should be included in the clinical study design, affecting clinical outcome or acting as mediating factors of the sex differences observed in clinical practice. The best recognized gender-related factors include: income, social status and supports, education, employment, social and physical environments, marital status, culture, and personal behaviors.

Sex and gender also affect health through several interactions: disease risk factors, symptoms, natural history, and outcomes as well as

Table 1. Main differences related to sex/gender in heart failure.

	Females	Males
Age of presentation	Higher incidence in elderly	Higher incidence in younger
Phenotype	HFpEF	HFrEF
Remodeling	Concentric	Eccentric
Comorbidity	Obesity, diabetes, hypertension	Ischemic heart disease
Rare (etiology peripartum, autoimmune, Takotsubo)	Frequent	Uncommon
Pharmacological therapy	Beta-blockers has slightly better effect	ACE-Inh and ARBs has slightly better effect
ICD	Less effective	More effective
CRT	More effective	Less effective

HFpEF: Heart Failure with preserved ejection fraction; HFrEF: Heart Failure with reduced ejection fraction; ICD: implantable cardio defibrillator; CRT: cardiac resynchronization therapy.

the response to drugs and non-pharmacological strategies are strongly influenced by these differences. A better understanding of this issue is mandatory, in order to obtain equal opportunity and same high-quality health care among people. Of note, gender impact remarkably on several cardiovascular conditions [6,68-71]. A hot topic is the need of a good and widely accepted method to report and evaluate the gender and sex related evidence deriving from research and how to apply this information into clinical practice. To accomplish this paradigm shift, it is important that clinical researchers have useful instruments to standardize and elucidate the role of sex and gender on health care. This might be accomplished through several steps. First, the importance of using the right terminology in medicine literature. Misuse of the terms sex and gender cannot be tolerated in scientific literature: the term sex should be used when reporting biological factors while the term gender when gender identity, psychosocial and cultural factors are described [58]. Second, design of clinical trials should allow researchers to disaggregate demographics and outcome data by sex and gender [58]. Third, it is important to obtain a good representation of the women in clinical trials, trying to enroll samples of patients that might mirror the prevalence of the sex-distribution on each disease. This could modify the unacceptable pitfalls involving cardiovascular diseases: even if they are the first cause of mortality and disability in women, most studies have been conducted in only in men. Risk factors for cardiovascular diseases influence men and women in a different way; clinical manifestations of diseases and drug influences display several sex and gender differences too [63,66].

Another aspect to consider it that biological and sociocultural factors differ substantially among individuals within each sex over their respective lives [72]. Profound changes associated for example with reproductive biology (such as occur at puberty and, in women, throughout the menstrual cycle, during pregnancy, and at menopause) and with aging are of the utmost importance in the expression of disease [60,63]. Women/female and men/males may present with different age, socioeconomic status, lifestyle (*e.g.* physical activity, diet, alcohol, use of tobacco, *etc.*), and other gendered behaviors and variables [63].

Conclusions and future perspectives

Table 1 presents a summary of the available differences in sex/gender in HF. Indeed, remarkable differences exist with regard to epidemiology, etiology, pathophysiology, presentations, phenotypes, response to treatment and prognosis. Several issues are still outstanding. First, women are still underrepresented in clinical trial, and this might lead to a lack of knowledge and gaps in treatment and management. Second, we still do not precisely know how to assess gender (more than easily sex assessment) and how much it impacts on clinical outcomes.

Finally, a raise in the awareness of the sex/gender issue is warranted. Future studies and research should focus on solving these relevant issues (as a prototype the ICD or CRT use in females and males with HF). Physicians should be more aware of these differences in order to get a tailored therapy of this clinical condition.

References

- Ambrosy AP, Fonarow GC, Butler J, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. *J Am Coll Cardiol* 2014;63:1123-33.
- Braunwald E. Heart failure. *JACC Heart Fail* 2013;1:1-20.
- Crespo-Leiro MG, Anker SD, Maggioni AP, et al. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. *Eur J Heart Fail* 2016;18:613-25.
- Chioncel O, Lainscak M, Seferovic PM, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. *Eur J Heart Fail* 2017;19:1574-85.
- D'Agostino RB, Grundy S, Sullivan LM, et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. *JAMA* 2001;286:180-7.
- Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. *N Engl J Med* 2002;347:1403-11.
- Mozaffarian D. Dietary and policy priorities for cardiovascular disease, diabetes, and obesity: A comprehensive review. *Circulation* 2016;133:187-225.
- Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. *J Am Coll Cardiol* 2004;43:317-27.
- Braunwald E. Heart failure. *JACC Heart Fail* 2013;1:1-20.
- Marra AM, Arcopinto M, Salzano A, et al. Detectable interleukin-9 plasma levels are associated with impaired cardiopulmonary functional capacity and all-cause mortality in patients with chronic heart failure. *Int J Cardiol* 2016;209:114-7.
- Cittadini A, Bossone E, Marra AM, et al. [Anabolic/catabolic imbalance in chronic heart failure]. [Article in Italian]. *Monaldi Arch Chest Dis* 2010;74:53-6.
- Cittadini A, Monti MG, Iaccarino G, et al. SOCS1 gene transfer accelerates the transition to heart failure through the inhibition of the gp130/JAK/STAT pathway. *Cardiovasc Res* 2012;96:381-90.
- Arcopinto M, Isgaard J, Marra AM, et al. IGF-1 predicts survival in chronic heart failure. Insights from the T.O.S.C.A. (Trattamento

- Ormonale Nello Scompenso Cardiaco) registry. *Int J Cardiol* 2014;176:1006-8.
14. Sirico D, Salzano A, Celentani D, et al. [Anti remodeling therapy: new strategies and future perspective in post-ischemic heart failure: Part I]. [Article in Italian]. *Monaldi Arch Chest Dis* 2014;82:187-94.
 15. Salzano A, Sirico D, Arcopinto M, et al. [Anti remodeling therapy: new strategies and future perspective in post-ischemic heart failure. Part II]. [Article in Italian]. *Monaldi Arch Chest Dis* 2014;82:195-201.
 16. Salzano A, Marra AM, Ferrara F, et al. Multiple hormone deficiency syndrome in heart failure with preserved ejection fraction. *Int J Cardiol* 2016;225:1-3.
 17. Arcopinto M, Salzano A, Giallauria F, et al. Growth hormone deficiency is associated with worse cardiac function, physical performance, and outcome in chronic heart failure: Insights from the T.O.S.C.A. GHD Study. *PLoS One* 2017;12:e0170058.
 18. Levinsson A, Dubé M-P, Tardif J-C, de Denuis S. Sex, drugs, and heart failure: a sex-sensitive review of the evidence base behind current heart failure clinical guidelines. *ESC Hear Fail* 2018; doi: 10.1002/ehf2.12307. [Epub ahead of print].
 19. Lam CSP, Carson PE, Anand IS, et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: The Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) Trial. *Circ Hear Fail* 2012;5:571-8.
 20. Galvao M, Kalman J, DeMarco T, et al. Gender differences in in-hospital management and outcomes in patients with decompensated heart failure: analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). *J Card Fail* 2006;12:100-7.
 21. Mosca S, Paolillo S, Colao A, et al. Cardiovascular involvement in patients affected by acromegaly: an appraisal. *Int J Cardiol* 2013;167:1712-8.
 22. Cittadini A, Marra AM, Arcopinto M, et al. Growth hormone replacement delays the progression of chronic heart failure combined with growth hormone deficiency. *JACC Hear Fail* 2013;1:325-30.
 23. Fazio S, Palmieri EA, Affuso F, et al. Effects of growth hormone on exercise capacity and cardiopulmonary performance in patients with chronic heart failure. *J Clin Endocrinol Metab* 2007;92:4218-23.
 24. Cittadini A, Monti MG, Castiello MC, et al. Insulin-like growth factor-1 protects from vascular stenosis and accelerates re-endothelialization in a rat model of carotid artery injury. *J Thromb Haemost* 2009;7:1920-8.
 25. Saccà F, Piro R, De Michele G, et al. Epoetin alfa increases frataxin production in Friedreich's ataxia without affecting hematocrit. *Mov Disord* 2011;26:739-42.
 26. Giannoulis MG, Boroujerdi MA, Powrie J, et al. Gender differences in growth hormone response to exercise before and after rhGH administration and the effect of rhGH on the hormone profile of fit normal adults. *Clin Endocrinol (Oxf)* 2005;62:315-22.
 27. Marra AM, Arcopinto M, Bobbio E, et al. An unusual case of dilated cardiomyopathy associated with partial hypopituitarism. *Intern Emerg Med* 2012;7(Suppl 2):S85-7.
 28. Bossone E, Limongelli G, Malizia G, et al. The T.O.S.C.A. Project: research, education and care. *Monaldi Arch Chest Dis* 2011;76:198-203.
 29. Pasquali D, Arcopinto M, Renzullo A, et al. Cardiovascular abnormalities in Klinefelter syndrome. *Int J Cardiol* 2013;168:754-59.
 30. Marra AM, Improda N, Capalbo D, et al. Cardiovascular abnormalities and impaired exercise performance in adolescents with congenital adrenal hyperplasia. *J Clin Endocrinol Metab* 2015;100:644-52.
 31. Salzano A, Arcopinto M, Marra AM, et al. Klinefelter syndrome, cardiovascular system, and thromboembolic disease: review of literature and clinical perspectives. *Eur J Endocrinol* 2016;175:R27-40.
 32. Salzano A, D'Assante R, Heaney LM, et al. Klinefelter syndrome, insulin resistance, metabolic syndrome, and diabetes: review of literature and clinical perspectives. *Endocrine* 2018;61:194-203.
 33. Bozkurt B, Khalaf S. Heart failure in women. *Methodist Debaquey Cardiovasc J* 13:216-23.
 34. Proietti M, Marra AM, Tassone EJ, et al. Frequency of left ventricular hypertrophy in non-valvular atrial fibrillation. *Am J Cardiol* 2015; 116:877-82.
 35. Grünig E, Biskupek J, D'Andrea A, et al. Reference ranges for and determinants of right ventricular area in healthy adults by two-dimensional echocardiography. *Respiration* 2015;89:284-93.
 36. Marra AM, Egenlauf B, Ehlken N, et al. Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. *Int J Cardiol* 2015;195:19-26.
 37. Ferrara F, Rudski LG, Vriz O, et al. Physiologic correlates of tricuspid annular plane systolic excursion in 1168 healthy subjects. *Int J Cardiol* 2016;223:736-43.
 38. Marra AM, Benjamin N, Ferrara F, et al. Reference ranges and determinants of right ventricle outflow tract acceleration time in healthy adults by two-dimensional echocardiography. *Int J Cardiovasc Imaging* 2017;33:219-26.
 39. Ferrara F, Gargani L, Ostenfeld E, et al. Imaging the right heart pulmonary circulation unit: Insights from advanced ultrasound techniques. *Echocardiography* 2017;34:1216-31.
 40. Ferrara F, Gargani L, Ruohonen S, et al. Reference values and correlates of right atrial volume in healthy adults by two-dimensional echocardiography. *Echocardiography* 2018;35:1097-107.
 41. Marra AM, Naeije R, Ferrara F, et al. Reference ranges and determinants of tricuspid regurgitation velocity in healthy adults assessed by two-dimensional Doppler echocardiography. *Respiration* 2018;1-9 doi: 10.1159/000490191 [Epub ahead of print].
 42. Bossone E, Lyon A, Citro R, et al. Takotsubo cardiomyopathy: an integrated multi-imaging approach. *Eur Heart J Cardiovasc Imaging* 2014;15:366-77.
 43. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. *N Engl J Med* 2002;347:1397-402.
 44. Keyzer JM, Hoffmann JJ, Ringoir L, et al. Age- and gender-specific brain natriuretic peptide (BNP) reference ranges in primary care. *Clin Chem Lab Med* 2014;52:1341-6.
 45. Redfield MM, Rodeheffer RJ, Jacobsen SJ, et al. Plasma brain natriuretic peptide concentration: impact of age and gender. *J Am Coll Cardiol* 2002;40:976-82.
 46. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J* 2016;37:2129-200.
 47. Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. *N Engl J Med* 2001;345:1667-75.
 48. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. *Lancet* 2000;355:1582-7.
 49. WRITING COMMITTEE MEMBERS CW, Yancy CW, Jessup M, et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society

- of America. *Circulation* 2016;134:e282-93. Erratum in: *Circulation* 2016;134:e298. doi: 10.1161/CIR.0000000000000460
50. Flather MD, Shibata MC, Coats AJS, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). *Eur Heart J* 2005;26:215-25.
 51. Ghanbari H, Dalloul G, Hasan R, et al. Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials. *Arch Intern Med* 2009;169:1500-6.
 52. Peterson PN, Daugherty SL, Wang Y, et al. Gender differences in procedure-related adverse events in patients receiving implantable cardioverter-defibrillator therapy. *Circulation* 2009;119:1078-84.
 53. Redberg RF. Don't assume women are the same as men: include them in the trial. *Arch Intern Med* 2012;172:921.
 54. Arshad A, Moss AJ, Foster E, et al. Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) trial. *J Am Coll Cardiol* 2011;57:813-20.
 55. Biton Y, Zareba W, Goldenberg I, et al. Sex differences in long-term outcomes with cardiac resynchronization therapy in mild heart failure patients with left bundle branch block. *J Am Heart Assoc* 2015;4: pii: e002013.
 56. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. *Circulation* 1993;88:107-15.
 57. Legato MJ, Johnson PA, Manson JE. Consideration of sex differences in medicine to improve health care and patient outcomes. *JAMA* 2016;316:1865-6.
 58. Clayton JA, Tannenbaum C. Reporting sex, gender, or both in clinical research? *JAMA* 2016;316:1863-64.
 59. Ventura-Clapier R, Dworatzek E, Seeland U, et al. Sex in basic research: concepts in the cardiovascular field. *Cardiovasc Res* 2017;113:711-24.
 60. Franconi F, Raparelli V, Regitz-Zagrosek V. Sex and gender landscape in pharmacology. *Pharmacol Res* 2017;123:93-4.
 61. Loikas D, Wettermark B, von Euler M, et al. Differences in drug utilisation between men and women: a cross-sectional analysis of all dispensed drugs in Sweden. *BMJ Open* 2013;3:e002378.
 62. Tannenbaum C, Greaves L, Graham ID. Why sex and gender matter in implementation research. *BMC Med Res Methodol* 2016;16:145.
 63. EUGenMed Cardiovascular Clinical Study Group, Regitz-Zagrosek V, Oertelt-Prigione S, et al. Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes. *Eur Heart J* 2016;37:24-34.
 64. Ulrich S, Hasler ED, Saxer S, et al. Effect of breathing oxygen-enriched air on exercise performance in patients with precapillary pulmonary hypertension: randomized, sham-controlled cross-over trial. *Eur Heart J* 2017;38:1159-68.
 65. Marra AM, Biskup E, Raparelli V, IMAGINE working group. The Internal Medicine and Assessment of Gender Differences in Europe (IMAGINE): The new European Federation of Internal Medicine initiative on sex and gender medicine. *Eur J Intern Med* 2018;51:e30-e32.
 66. Pelletier R, Khan NA, Cox J, et al. Sex versus gender-related characteristics. *J Am Coll Cardiol* 2016;67:127-35.
 67. Pelletier R, Ditto B, Pilote L. A composite measure of gender and its association with risk factors in patients with premature acute coronary syndrome. *Psychosom Med* 2015;77:517-26.
 68. Di Giosia P, Passacuale G, Petrarca M, et al. Gender differences in cardiovascular prophylaxis: Focus on antiplatelet treatment. *Pharmacol Res* 2017;119:36-47.
 69. Marra AM, Benjamin N, Eichstaedt C, et al. Gender-related differences in pulmonary arterial hypertension targeted drugs administration. *Pharmacol Res* 2016;114:103-9.
 70. Salzano A, Demelo-Rodriguez P, Marra AM, Proietti M. A focused review of gender differences in antithrombotic therapy. *Curr Med Chem* 2017;24:2576-88.
 71. Marra AM, Egenlauf B, Bossone E, et al. Principles of rehabilitation and reactivation: pulmonary hypertension. *Respiration* 2015;89:265-73.
 72. Seeland U, Nauman AT, Cornelis A, et al. eGender-from e-Learning to e-Research: a web-based interactive knowledge-sharing platform for sex- and gender-specific medical education. *Biol Sex Differ* 2016;7(Suppl 1):39.